Ralmitaront

Ralmitaront
Clinical data
Other namesRG-7906; RO-6889450
Identifiers
IUPAC name
  • 5-Ethyl-4-methyl-N-[4-[(2S)-morpholin-2-yl]phenyl]-1H-pyrazole-3-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC17H22N4O2
Molar mass314.389 g·mol−1
3D model (JSmol)
SMILES
  • CCC1=C(C(=NN1)C(=O)NC2=CC=C(C=C2)[C@H]3CNCCO3)C
InChI
  • InChI=1S/C17H22N4O2/c1-3-14-11(2)16(21-20-14)17(22)19-13-6-4-12(5-7-13)15-10-18-8-9-23-15/h4-7,15,18H,3,8-10H2,1-2H3,(H,19,22)(H,20,21)/t15-/m1/s1
  • Key:XHHXGKRFUPEPFM-OAHLLOKOSA-N

Ralmitaront (INN, USAN; developmental code names RG-7906 and RO-6889450) is an investigational antipsychotic drug which is undergoing clinical trials for the treatment of acute exacerbation of schizophrenia and schizoaffective disorder.[1][2][3] It is a partial agonist of the TAAR1.[4] The medication is being developed by the pharmaceutical company Hoffmann-La Roche.[1] Ralmitaront has completed phase 1 clinical trials.[1][5] Phase 2 trials are ongoing.[1][6]

See also

References

  1. 1 2 3 4 "Ralmitaront - Roche". AdisInsight. Springer Nature Switzerland AG.
  2. ↑ Clinical trial number NCT04512066 for "A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder" at ClinicalTrials.gov
  3. ↑ Gomes FV, Grace AA (April 2021). "Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention". International Journal of Molecular Sciences. 22 (9): 4467. doi:10.3390/ijms22094467. PMC 8123139. PMID 33922888.
  4. ↑ "Ralmitaront: Relationships: Trace Amine-Associated Receptor 1". Global Substance Registration System (GSRS). U.S. Food and Drug Administration.{{cite web}}: CS1 maint: url-status (link)
  5. ↑ Clinical trial number NCT02699372 for "The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of RO6889450 in Healthy Volunteers" at ClinicalTrials.gov
  6. ↑ Clinical trial number NCT04512066 for "A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder" at ClinicalTrials.gov


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.